CatalYm has identified GDF-15 as a central regulator of the immune system in the tumor microenvironment. We are pioneering the reversal of GDF-15-mediated immunosuppression to induce a potent antitumoral immune reaction in non-responsive tumors. CatalYm's lead program visugromab (CTL-002) is poised to demonstrate clinical proof-of-concept in multiple solid tumor indications which will expand the treatment horizon for current and future immunotherapies.
View Top Employees from CatalYm GmbH| Website | http://www.catalym.com |
| Revenue | $2 million |
| Employees | 47 (32 on RocketReach) |
| Phone | +49 89 200066440 |
| Technologies |
JavaScript,
HTML,
PHP
+13 more
(view full list)
|
| Industry | Biotechnology Research, Business Services General, Therapeutics, Business Services, Health Care |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 541 Companies, NAICS Code 541713 Companies |
Looking for a particular CatalYm GmbH employee's phone or email?
CatalYm GmbH Questions
The CatalYm GmbH annual revenue was $2 million in 2024.
Phil L'Huillier is the CEO of CatalYm GmbH.
32 people are employed at CatalYm GmbH.
The NAICS codes for CatalYm GmbH are [54, 5417, 54171, 541, 541713].
The SIC codes for CatalYm GmbH are [873, 87].
Top CatalYm GmbH Employees
-
21
-
ViewThorsten Ross
VP Preclinical Research & Translation Strategy at CatalYm GmbH
Heidelberg, BW, DE1 -
41
-
1
-
2
-
1
-
Related Companies
